Baotou Dongbao Bio-TechLtd Performance dei guadagni passati
Il passato criteri di controllo 2/6
Baotou Dongbao Bio-TechLtd has been growing earnings at an average annual rate of 35.5%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 18.3% per year. Baotou Dongbao Bio-TechLtd's return on equity is 5.6%, and it has net margins of 10.4%.
Informazioni chiave
35.5%
Tasso di crescita degli utili
32.9%
Tasso di crescita dell'EPS
Chemicals Crescita del settore | 12.1% |
Tasso di crescita dei ricavi | 18.3% |
Rendimento del capitale proprio | 5.6% |
Margine netto | 10.4% |
Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price Boost
Oct 08We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)
Oct 01Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022
May 27Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)
Feb 28Ripartizione dei ricavi e delle spese
Come Baotou Dongbao Bio-TechLtd guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Sep 24 | 873 | 91 | 66 | 22 |
30 Jun 24 | 898 | 106 | 66 | 22 |
31 Mar 24 | 955 | 115 | 68 | 24 |
31 Dec 23 | 975 | 120 | 72 | 26 |
30 Sep 23 | 972 | 117 | 69 | 29 |
30 Jun 23 | 988 | 116 | 70 | 28 |
31 Mar 23 | 977 | 117 | 68 | 27 |
01 Jan 23 | 943 | 109 | 68 | 26 |
30 Sep 22 | 906 | 111 | 64 | 23 |
30 Jun 22 | 812 | 87 | 56 | 20 |
31 Mar 22 | 702 | 56 | 50 | 16 |
01 Jan 22 | 612 | 36 | 40 | 13 |
30 Sep 21 | 560 | 22 | 29 | 8 |
30 Jun 21 | 539 | 19 | 32 | 9 |
31 Mar 21 | 497 | 20 | 30 | 9 |
31 Dec 20 | 449 | 18 | 32 | 10 |
30 Sep 20 | 454 | 20 | 43 | 11 |
30 Jun 20 | 448 | 22 | 42 | 11 |
31 Mar 20 | 469 | 29 | 43 | 12 |
31 Dec 19 | 492 | 33 | 45 | 11 |
30 Sep 19 | 470 | 35 | 43 | 11 |
30 Jun 19 | 454 | 35 | 43 | 11 |
31 Mar 19 | 467 | 35 | 45 | 11 |
31 Dec 18 | 453 | 34 | 45 | 10 |
30 Sep 18 | 436 | 30 | 46 | 8 |
30 Jun 18 | 424 | 27 | 42 | 11 |
31 Mar 18 | 378 | 24 | 41 | 8 |
31 Dec 17 | 356 | 22 | 40 | 6 |
30 Sep 17 | 330 | 22 | 37 | 5 |
30 Jun 17 | 318 | 23 | 43 | 0 |
31 Mar 17 | 314 | 22 | 44 | 0 |
31 Dec 16 | 317 | 19 | 45 | 0 |
30 Sep 16 | 320 | 14 | 49 | 0 |
30 Jun 16 | 311 | 10 | 45 | 0 |
31 Mar 16 | 305 | 7 | 41 | 0 |
31 Dec 15 | 292 | 6 | 38 | 0 |
30 Sep 15 | 279 | 7 | 31 | 0 |
30 Jun 15 | 275 | 5 | 31 | 0 |
31 Mar 15 | 260 | 4 | 32 | 0 |
31 Dec 14 | 251 | 5 | 32 | 0 |
30 Sep 14 | 259 | 12 | 34 | 0 |
30 Jun 14 | 288 | 22 | 33 | 0 |
31 Mar 14 | 338 | 31 | 38 | 0 |
31 Dec 13 | 382 | 43 | 39 | 0 |
Guadagni di qualità: 300239 has high quality earnings.
Margine di profitto in crescita: 300239's current net profit margins (10.4%) are lower than last year (12%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 300239's earnings have grown significantly by 35.5% per year over the past 5 years.
Accelerare la crescita: 300239's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Guadagni vs Settore: 300239 had negative earnings growth (-22.3%) over the past year, making it difficult to compare to the Chemicals industry average (-3.8%).
Rendimento del capitale proprio
ROE elevato: 300239's Return on Equity (5.6%) is considered low.